PFIZER INC — Director's Dealing 2022

Feb 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2022-02-23

Reporting Person: McDermott Michael (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-23	Common Stock	M	14952.0000	$27.3400	Acquired	81518.0000	Direct
2022-02-23	Common Stock	F	2927.0000	$46.8700	Disposed	78591.0000	Direct
2022-02-23	Common Stock	F	7401.0000	$51.2800	Disposed	71190.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-23	Stock Appreciation Rights	$27.3400	M	14952.0000	Disposed	2022-02-23	Common Stock (14952.0000)	Direct
2022-02-24	Stock Appreciation Rights	$45.9600	A	34234.0000	Acquired	2027-02-24	Common Stock (34234.0000)	Direct
2022-02-24	Stock Appreciation Rights	$45.9600	A	30109.0000	Acquired	2029-02-24	Common Stock (30109.0000)	Direct

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F5: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F6: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.